GT Biopharma Restates Q2 2025 Financials, Revealing $28.7M Liability & Negative Equity
GTBP sits 17% above its 52-week low of $0.401 on light trading volume (0.3× avg).
Summary
GT Biopharma restated its Q2 2025 financials, revealing a $28.7 million Greenshoe Rights liability, which caused stockholders' equity to turn significantly negative and dramatically increased net loss, highlighting severe financial distress and renewed Nasdaq delisting risk.
Key Events · Corporate Governance and Compliance · GTBP
-
Material Financial Restatement
The company restated its Quarterly Report for June 30, 2025, to correct a material error in classifying $28.7 million in 'Greenshoe Rights' as a liability, which were previously unrecognized.
-
Significant Financial Deterioration
The restatement caused total liabilities to increase by $28.7 million and swung stockholders' equity from a positive $2.86 million to a negative $25.88 million as of June 30, 2025. Net loss for the quarter increased from $(1.43) million to $(30.17) million.
-
Material Weakness in Internal Controls
Management concluded that disclosure controls and procedures were ineffective as of June 30, 2025, due to errors in accounting for complex financial transactions, constituting a material weakness.
-
Renewed Nasdaq Delisting Risk
The restated negative stockholders' equity of $(25.88) million likely puts the company back out of compliance with Nasdaq's minimum listing requirement of $2.5 million, despite a prior notification of regaining compliance.
Analysis · GTBP · Life Sciences
GT Biopharma, Inc. filed an amended Quarterly Report (10-Q/A) to restate its financial statements for the quarter ended June 30, 2025. The restatement corrects a material error related to the classification of $28.7 million in 'Greenshoe Rights' as a liability, which were previously not recognized. This reclassification significantly impacts the company's financial position, increasing total liabilities by $28.7 million and swinging stockholders' equity from a previously reported positive $2.86 million to a negative $25.88 million. The net loss for the quarter also dramatically increased from $(1.43) million to $(30.17) million. This substantial financial deterioration, coupled with the disclosure of a material weakness in internal controls, raises severe concerns about the company's financial health and its ability to maintain Nasdaq listing compliance, despite a prior notification of regaining compliance. Subsequent events also indicate further dilutive activities.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.8% of the 571 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GTBP was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.8M. The 52-week trading range was $0.40 to $3.85. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.